Eyeworld

Benefits of 503B Sterile compounding in the ophthalmic field is a specialized approach crucial to patient care. Empowered to manufacture large medication batches, OSRX now oers: Bulk ordering sent to facilities Lowered medication costs Increased quality assurance Savings for patients OSRX continues to support patient-specific prescriptions delivered directly to patient homes. The Facility The FDA-registered 503B will operate from its new 5,300 sq. ft. state-of-the-art facility in Missoula, MT, equipped with cutting-edge technology, ensuring enhanced productivity while maintaining Current Good Manufacturing Practices (cGMP) quality. "We are applying OSRX's expertise, talent, and commitment to quality to ensure our 503B business meets CGMP standards and align with the FDA's requirements for outsourcing facilities," says Chief Pharmacy Oicer Amy Frost, another key leader in this exciting venture for OSRX. "It's been a challenging, but very rewarding journey. Instead of only being able to ship patient-specific prescriptions, we can now transport in bulk directly to medical facilities. It's a win-win for prescribers and their patients." Great News for High-volume Practices Chirag Shah, MD, is a board certified ophthalmologist and the founder of LASIK Experts in New Jersey and Pennsylvania. Having trusted OSRX post-op eye drops for his high-volume practice, he is excited about the 503B announcement. "With this new status, OSRX bulk ordering will help remove barriers, making quality medications more accessible to patients. The drops we receive from OSRX are predictable with consistent high-quality medications in each bottle." Advertorial Giddy Up: OSRX Says 'There's a New Sheriff in Town' *For professional use only. OSRX specializes in customizing compounded medications to meet unique patient and practitioner needs. Compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, e•ectiveness, and quality. OSRX medications carry serious risks. View potential adverse events and contraindications at: www.osrxpharmaceuticals.com/osrx-api-aecontraindication. This insert was independently produced by OSRX, Inc. EyeWorld had no part in its production. The views expressed here do not necessarily reflect those of the editor, editorial board, or the publisher, and in no way imply endorsement by EyeWorld or ASCRS. OSRX® Pharmaceuticals recently achieved its new status as a 503B outsourcing facility, marking a significant leap toward becoming the top ophthalmic compounder nationwide. Guided by Founder and CEO Anthony Sampietro, OSRX is set to expand its services to allow doctors to bulk order OMNI by OSRX® ophthalmic formulations to their private practices, hospitals, and ambulatory surgery centers. Quality is Top Priority "Since 2017, our company has been predicated on providing simple, aordable and quality solutions for pre- and post-op care with white-glove treatment," says Sampietro. "We will continue our long-standing service model. OSRX as a 503B is an expansion of services, not a change. We are not altering what made us who we are." About OSRX OSRX is an FDA-registered 503B outsourcing facility committed to transforming ophthalmic care through quality compounded solutions. The Missoula, MT-based company is on a mission to redefine the landscape of the corrective eye care market with a focus on simplicity, aordability and patient-centric care. Trusted by more than 5,500 prescribers across the U.S., OSRX is providing A New View of Medicine®. Learn more at www.osrxpharmaceuticals.com. The Montana-based pharmacy has achieved 503B status and is gunning to become the top compounder – not just out West – but in all of ophthalmology.

• Cover